Form 4: Catalyst Pharma Officer's Equity Transactions

Catalyst Pharmaceuticals' Chief Compliance/Legal Officer, Brian Elsbernd, reported recent acquisitions of common stock, options, and restricted stock units, alongside tax-related share disposals.

Summary

• Brian Elsbernd, Chief Compliance/Legal Officer of Catalyst Pharmaceuticals, Inc. (CPRX), reported several equity transactions.
• On November 21, 2025, Elsbernd acquired 5,161 shares of common stock, increasing his direct beneficial ownership to 236,200 shares.
• Concurrently, 2,030 shares were disposed of to satisfy tax withholding obligations upon the vesting of restricted common stock, resulting in a post-transaction beneficial ownership of 234,170 shares.
• On November 20, 2025, Elsbernd was granted 98,652 options to purchase common stock at an exercise price of $22.77, vesting in three equal annual tranches starting November 20, 2026, and expiring on November 20, 2032.
• Also on November 20, 2025, 29,776 Restricted Stock Units (RSUs) were acquired, vesting in three equal annual tranches starting November 20, 2026.
• On November 21, 2025, 5,161 Restricted Stock Units (RSUs) were acquired, with the first tranche vesting and being delivered on the same day, and subsequent tranches vesting on November 21, 2026, and November 21, 2027.
• All reported transactions were made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 6

Explanation: The filing reports routine insider equity compensation and tax-related transactions, which are generally neutral but slightly positive as they indicate continued alignment of management with shareholder interests through equity ownership. The transactions are part of an expected compensation structure.

Positives

• Acquisition of additional equity (options and RSUs) by a key officer indicates continued alignment of management interests with shareholder value.
• The vesting of RSUs and exercise of options represent compensation for the officer, reflecting ongoing commitment to the company.

Negatives

• Disposal of 2,030 shares for tax withholding purposes is a standard practice and not inherently negative, but it does reduce direct share count.

Future Outlook

This filing does not contain specific forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This filing details specific insider equity transactions for Catalyst Pharmaceuticals and does not provide broader industry context or trends.

Stakeholder Impact

• Shareholders: The transactions demonstrate continued alignment of a key officer's interests with shareholders through equity ownership, which can be viewed positively. The tax-related sales are routine and have minimal impact.
• Employees: These transactions reflect standard executive compensation practices, which may influence overall employee compensation structures and morale.

Next Steps

• Future vesting of options and restricted stock units on specified dates (11/20/2026, 11/21/2026, 11/20/2027, 11/21/2027, 11/20/2028).
• Delivery of common stock to the reporting person within sixty days of vesting for the 5,161 RSUs.

Key Dates

Recommendation

The filing details routine insider transactions related to executive compensation, specifically the vesting of restricted stock units and the grant of stock options, along with a standard tax-related share disposal. These are expected events under a Rule 10b5-1 plan and do not indicate any material change in the company's fundamentals or strategic direction. While the officer's increased equity stake is a minor positive for alignment, the overall impact on investment thesis is neutral, warranting a 'hold' recommendation based solely on this filing.

Keywords

Catalyst Pharmaceuticals, CPRX, Brian Elsbernd, Form 4, Insider Trading, Stock Options, Restricted Stock Units, Equity Compensation, SEC Filing, Officer Transactions, Rule 10b5-1